The TCF4 Gene Regulates Apoptosis of Corneal Endothelial Cells in Fuchs Endothelial Corneal Dystrophy

Overview

Journal Invest Ophthalmol Vis Sci

Specialty Ophthalmology

Date 2025 Mar 6

PMID 40048186

Authors

Tatsuya Nakagawa

Tetsuro Honda

Taichi Yuasa

Go Nishiuchi

Masakazu Sato

Ayumi Tokunaga

Makiko Nakahara

Theofilos Tourtas

Ursula Schlotzer-Schrehardt

Friedrich Kruse

Prema Padmanabhan

Amit Chatterjee

Gajanan Sathe

Vivek Ghose

Narayanan Janakiraman

Derek J Blake

Noriko Koizumi

Sailaja Elchuri

Naoki Okumura

Affiliations

Soon will be listed here.

Abstract

Purpose: Fuchs endothelial corneal dystrophy (FECD) is a progressive corneal disorder characterized by excessive extracellular matrix (ECM) accumulation and corneal endothelial cell death. CTG trinucleotide repeat expansion in the transcription factor 4 (TCF4) gene represents the most significant genetic risk factor. This study aimed to elucidate the role of TCF4 in FECD pathogenesis through comprehensive proteomic analysis.

Methods: Corneal endothelial cells isolated from patients with FECD harboring TCF4 trinucleotide repeat expansion were immortalized to establish an FECD cell model (iFECD). CRISPR/Cas9-mediated genome editing was employed to generate TCF4-knockout iFECD cells. Whole-cell proteome analysis was performed using liquid chromatography-mass spectrometry, followed by pathway enrichment analysis of differentially expressed proteins (DEPs). The effects of TCF4 deletion on TGF-β-mediated protein aggregation and cell death were evaluated using Western blot analysis, flow cytometry, and aggresome detection assays.

Results: Proteomic analysis identified 88 DEPs among 6510 detected proteins. Pathway analysis revealed significant enrichment in ECM-associated pathways, oxidative stress responses, and cellular motility. TCF4 deletion attenuated TGF-β-induced cell death in iFECD cells. Concordantly, Western blot analysis demonstrated that TCF4 deletion suppressed TGF-β2-mediated cleavage of caspase-3 and poly (ADP-ribose) polymerase. Flow cytometric analysis of Annexin V-positive cells confirmed reduced apoptosis in TCF4-deleted cells following TGF-β2 treatment. Additionally, aggresome detection assays revealed that TCF4 deletion diminished TGF-β2-induced protein aggregation.

Conclusions: This study demonstrates a crucial role for TCF4 in FECD pathogenesis, particularly in ECM regulation and protein aggregation-induced cell death.

References

Eghrari A, Vahedi S, Afshari N, Riazuddin S, Gottsch J . CTG18.1 Expansion in TCF4 Among African Americans With Fuchs' Corneal Dystrophy. Invest Ophthalmol Vis Sci. 2017; 58(14):6046-6049. PMC: 5710628. DOI: 10.1167/iovs.17-21661. View

Zhang C, Wei S, Sun W, Teng K, Dai M, Wang F . Super-enhancer-driven AJUBA is activated by TCF4 and involved in epithelial-mesenchymal transition in the progression of Hepatocellular Carcinoma. Theranostics. 2020; 10(20):9066-9082. PMC: 7415796. DOI: 10.7150/thno.45349. View

Riazuddin S, Vithana E, Seet L, Liu Y, Al-Saif A, Koh L . Missense mutations in the sodium borate cotransporter SLC4A11 cause late-onset Fuchs corneal dystrophy. Hum Mutat. 2010; 31(11):1261-8. PMC: 2970683. DOI: 10.1002/humu.21356. View

Kuyumcu-Martinez N, Wang G, Cooper T . Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell. 2007; 28(1):68-78. PMC: 2083558. DOI: 10.1016/j.molcel.2007.07.027. View

Forrest M, Waite A, Martin-Rendon E, Blake D . Knockdown of human TCF4 affects multiple signaling pathways involved in cell survival, epithelial to mesenchymal transition and neuronal differentiation. PLoS One. 2013; 8(8):e73169. PMC: 3751932. DOI: 10.1371/journal.pone.0073169. View

Rong Z, Hu J, Corey D, Mootha V . Quantitative Studies of Muscleblind Proteins and Their Interaction With TCF4 RNA Foci Support Involvement in the Mechanism of Fuchs' Dystrophy. Invest Ophthalmol Vis Sci. 2019; 60(12):3980-3991. PMC: 6779288. DOI: 10.1167/iovs.19-27641. View

Okumura N, Hashimoto K, Kitahara M, Okuda H, Ueda E, Watanabe K . Activation of TGF-β signaling induces cell death via the unfolded protein response in Fuchs endothelial corneal dystrophy. Sci Rep. 2017; 7(1):6801. PMC: 5533742. DOI: 10.1038/s41598-017-06924-3. View

Martinowich K, Das D, Sripathy S, Mai Y, Kenney R, Maher B . Evaluation of Na1.8 as a therapeutic target for Pitt Hopkins Syndrome. Mol Psychiatry. 2022; 28(1):76-82. DOI: 10.1038/s41380-022-01811-4. View

Krachmer J, Purcell Jr J, Young C, Bucher K . Corneal endothelial dystrophy. A study of 64 families. Arch Ophthalmol. 1978; 96(11):2036-9. DOI: 10.1001/archopht.1978.03910060424004. View

10.

Eghrari A, Riazuddin S, Gottsch J . Fuchs Corneal Dystrophy. Prog Mol Biol Transl Sci. 2015; 134:79-97. DOI: 10.1016/bs.pmbts.2015.04.005. View

11.

Afshari N, Igo Jr R, Morris N, Stambolian D, Sharma S, Pulagam V . Genome-wide association study identifies three novel loci in Fuchs endothelial corneal dystrophy. Nat Commun. 2017; 8:14898. PMC: 5379100. DOI: 10.1038/ncomms14898. View

12.

Soragni E, Petrosyan L, Rinkoski T, Wieben E, Baratz K, Fautsch M . Repeat-Associated Non-ATG (RAN) Translation in Fuchs' Endothelial Corneal Dystrophy. Invest Ophthalmol Vis Sci. 2018; 59(5):1888-1896. PMC: 5886103. DOI: 10.1167/iovs.17-23265. View

13.

Zarouchlioti C, Sanchez-Pintado B, Hafford Tear N, Klein P, Liskova P, Dulla K . Antisense Therapy for a Common Corneal Dystrophy Ameliorates TCF4 Repeat Expansion-Mediated Toxicity. Am J Hum Genet. 2018; 102(4):528-539. PMC: 5985359. DOI: 10.1016/j.ajhg.2018.02.010. View

14.

Winkler N, Milone M, Martinez-Thompson J, Raja H, Aleff R, Patel S . Fuchs' Endothelial Corneal Dystrophy in Patients With Myotonic Dystrophy, Type 1. Invest Ophthalmol Vis Sci. 2018; 59(7):3053-3057. PMC: 6005624. DOI: 10.1167/iovs.17-23160. View

15.

Joshi-Tope G, Gillespie M, Vastrik I, DEustachio P, Schmidt E, de Bono B . Reactome: a knowledgebase of biological pathways. Nucleic Acids Res. 2004; 33(Database issue):D428-32. PMC: 540026. DOI: 10.1093/nar/gki072. View

16.

Okumura N, Hayashi R, Nakano M, Yoshii K, Tashiro K, Sato T . Effect of Trinucleotide Repeat Expansion on the Expression of TCF4 mRNA in Fuchs' Endothelial Corneal Dystrophy. Invest Ophthalmol Vis Sci. 2019; 60(2):779-786. PMC: 6392475. DOI: 10.1167/iovs.18-25760. View

17.

Harris M, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R . The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 2003; 32(Database issue):D258-61. PMC: 308770. DOI: 10.1093/nar/gkh036. View

18.

Wieben E, Aleff R, Eckloff B, Atkinson E, Baheti S, Middha S . Comprehensive assessment of genetic variants within TCF4 in Fuchs' endothelial corneal dystrophy. Invest Ophthalmol Vis Sci. 2014; 55(9):6101-7. PMC: 4179444. DOI: 10.1167/iovs.14-14958. View

19.

Quednow B, Brzozka M, Rossner M . Transcription factor 4 (TCF4) and schizophrenia: integrating the animal and the human perspective. Cell Mol Life Sci. 2014; 71(15):2815-35. PMC: 11113759. DOI: 10.1007/s00018-013-1553-4. View

20.

Ong Tone S, Kocaba V, Bohm M, Wylegala A, White T, Jurkunas U . Fuchs endothelial corneal dystrophy: The vicious cycle of Fuchs pathogenesis. Prog Retin Eye Res. 2020; 80:100863. PMC: 7648733. DOI: 10.1016/j.preteyeres.2020.100863. View